Nanobiotix Spon Ads Each Rep 1 Ord Shs (NBTX) Stock
Clinical biotech company enhancing radiation treatment for cancer. Here's the price, business snapshot, and what's worth knowing about Nanobiotix Spon Ads Each Rep 1 Ord Shs in July 2026.
Nanobiotix SA (ADR: NBTX) is a clinical-stage biotechnology company focused on physics-based therapeutics that enhance radiotherapy for solid tumours. Its lead candidate, NBTXR3 (marketed as Hensify in some jurisdictions), are tumour-injected crystalline nanoparticles designed to amplify the local effect of ionising radiation. The company is headquartered in France and listed as an American Depositary Receipt in the US, with multiple Phase II/III programmes and investigator-led studies across indications such as soft-tissue sarcoma and head and neck cancers. As a clinical-stage stock, progress is driven by trial outcomes, regulatory decisions and partnership or commercial execution; revenues are limited and further financing may be required. Market capitalisation is about $1.13bn. This summary is educational only and not personalised investment advice — suitability depends on your circumstances. Remember values can rise and fall and returns are not guaranteed.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Nanobiotix stock, expecting it to rise from its current price.
Financial Health
Nanobiotix is generating modest revenue and cash flow, indicating steady operations but limited growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring NBTX
Radiopharma Revolution: Promise Meets Market Risk
Aktis Oncology's highly successful and upsized IPO, strongly backed by pharma giant Eli Lilly, signals a surge of investor confidence in radiopharmaceutical cancer therapies. This theme focuses on the companies poised to ride this wave of investment and innovation in one of biotech's most promising frontiers.
Published: 9 January 2026
Explore BasketRNA Stocks (M&A Targets) Could See Premium Valuations
Novartis's $12 billion acquisition of Avidity Biosciences underscores the high value of RNA-based treatments for rare diseases. This deal could spark a wave of similar acquisitions, creating opportunities for other biotech companies with innovative RNA platforms.
Published: 27 October 2025
Explore BasketCancer Drug Safety: Could Warnings Create Opportunities?
The FDA's decision to add its strongest safety warning to a key cancer therapy from Johnson & Johnson and Legend Biotech underscores the inherent risks of powerful new treatments. This regulatory action could boost companies developing safer alternative cancer therapies, creating a new investment opportunity in the biotech sector.
Published: 11 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts ahead
Several ongoing trials may provide meaningful data points that could de‑risk the story, though outcomes are binary and timelines can be long.
Physics-based approach
NBTXR3 amplifies radiotherapy locally and may complement existing cancer treatments; adoption depends on convincing clinical evidence and regulatory acceptance.
Commercial and funding
Limited commercial approvals and partnerships could support growth, but rollout complexity and potential funding needs are important considerations for investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
